Ticker > Company >

Ipca Laboratories share price

Ipca Laboratories Ltd.

NSE: IPCALAB BSE: 524494 SECTOR: Pharmaceuticals & Drugs  148k   677   90

1537.45
+42.45 (2.84%)
BSE: 06 Dec 04:00 PM

Price Summary

Today's High

₹ 1541.95

Today's Low

₹ 1503.9

52 Week High

₹ 1708.7

52 Week Low

₹ 1042

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

39005.75 Cr.

Enterprise Value

40025.74 Cr.

No. of Shares

25.37 Cr.

P/E

60.01

P/B

5.79

Face Value

₹ 1

Div. Yield

0.26 %

Book Value (TTM)

₹  265.61

CASH

112.92 Cr.

DEBT

1132.91 Cr.

Promoter Holding

46.3 %

EPS (TTM)

₹  25.62

Sales Growth

6.05%

ROE

8.68 %

ROCE

12.78%

Profit Growth

4.89 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 26 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.05%
3 Year6.19%
5 Year11.18%

Profit Growth

1 Year4.89%
3 Year-22.53%
5 Year3.12%

ROE%

1 Year8.68%
3 Year11.47%
5 Year16.14%

ROCE %

1 Year12.78%
3 Year14.63%
5 Year19.06%

Debt/Equity

0.1784

Price to Cash Flow

46.97

Interest Cover Ratio

7.7071

CFO/PAT (5 Yr. Avg.)

1.10632271912969

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 46.30 0.00
Jun 2024 46.30 0.00
Mar 2024 46.30 0.00
Dec 2023 46.29 0.00
Sep 2023 46.29 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 20.9497180124806% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 70.5224 days.
  • Company has a healthy liquidity position with current ratio of 2.3089.
  • The company has a good cash flow management; CFO/PAT stands at 1.10632271912969.

 Limitations

  • The company has shown a poor profit growth of -22.5292303461093% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.19144481483929% for the Past 3 years.
  • The company is trading at a high PE of 60.01.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 1662.66 1506.83 1510.62 1565.86 1810.94
Total Expenditure 1314.39 1233.34 1218.28 1212.62 1408.83
Operating Profit 348.27 273.49 292.34 353.24 402.11
Other Income 36.14 16.89 15.1 15.39 17
Interest 38.64 27.21 24.06 19.42 17.25
Depreciation 61.35 63.02 61.76 61.32 62.65
Exceptional Items -39.29 0 -94.32 0 0
Profit Before Tax 245.13 200.15 127.3 287.89 339.21
Tax 83 63.21 62.54 83.76 95.09
Profit After Tax 162.13 136.94 64.76 204.13 244.12
Adjusted EPS (Rs) 6.39 5.4 2.55 8.05 9.62

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 4337.82 5114.11 5405.42 5774.72 6124.06
Total Expenditure 3439.48 3663.9 4220.01 4886.6 4959.25
Operating Profit 898.34 1450.21 1185.41 888.12 1164.81
Other Income 84.16 128.6 108.76 137.34 159.77
Interest 18.84 11.13 10.41 46.34 122.58
Depreciation 178.69 187.72 209.65 228.63 246.48
Exceptional Items 0 0 0 0 -133.36
Profit Before Tax 784.97 1379.96 1074.11 750.49 822.16
Tax 132.51 239.19 213.74 244.79 291.75
Net Profit 652.46 1140.77 860.37 505.7 530.41
Adjusted EPS (Rs.) 25.82 44.97 33.91 19.93 20.91

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 25.27 25.37 25.37 25.37 25.37
Total Reserves 3652.27 4727.35 5450.39 5851.93 6323.34
Borrowings 78.38 9.13 395.18 651.78 542.19
Other N/C liabilities 187.05 182.69 213.77 240.11 248.2
Current liabilities 1241.6 1065.59 1353.73 1677.78 1520.17
Total Liabilities 5184.57 6010.13 7438.44 8446.97 8659.27
Assets
Net Block 1840.97 1868.6 2153.09 2478.66 2523.7
Capital WIP 69.77 180.85 293.37 114.31 165.59
Intangible WIP 14.42 1.15 3.78 8.71 9.61
Investments 410.47 474.01 619.39 733.41 2243.56
Loans & Advances 125.65 183.45 119.21 227.77 186.16
Other N/C Assets 11.18 24.28 25.14 8.96 20.76
Current Assets 2712.11 3277.79 4224.46 4875.15 3509.89
Total Assets 5184.57 6010.13 7438.44 8446.97 8659.27
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 784.97 1379.96 1074.11 750.49 822.16
Adjustment 180.77 172.5 221.16 206.09 399.16
Changes in Assets & Liabilities -257.9 -214.53 -271.39 20.96 -113.86
Tax Paid -146.41 -241.87 -192.16 -215.25 -276.95
Operating Cash Flow 561.43 1096.06 831.72 762.29 830.51
Investing Cash Flow -499.13 -559.56 -811.85 -709.61 -1355.18
Financing Cash Flow -138.67 -307.38 426.04 506.38 -464.88
Net Cash Flow -76.37 229.12 445.91 559.06 -989.55

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 46.29 46.29 46.30 46.30 46.30
chandurkar investments pr... 5.50 5.50 5.50 5.50 5.50
kalpana jain 0.09 0.09 0.09 0.09 0.09
kaygee investments privat... 21.47 21.47 21.47 21.47 21.47
kaygee laboratories priva... 6.61 6.61 6.61 6.61 6.61
mexin medicaments private... 0.01 0.01 0.01 0.01 0.01
paschim chemicals pvt ltd... 4.00 4.00 4.01 4.01 4.01
pranay godha 0.67 0.67 0.67 0.67 0.67
prashant godha 0.62 0.62 0.62 0.62 0.62
premchand godha 2.29 2.29 2.29 2.29 2.29
sameer m chandurkar 0.79 0.79 0.79 0.79 0.79
usha m chandurkar 3.27 3.27 3.27 3.27 3.27
usha premchand godha 0.95 0.95 0.95 0.95 0.95
xbees traders llp 0.01 0.01 0.01 0.01 0.01
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 53.71 53.71 53.70 53.70 53.70
dsp midcap fund 6.73 6.90 7.13 6.43 5.97
hdfc life insurance compa... 1.90 1.97 1.95 1.95 1.93
hdfc mutual fund - hdfc m... 7.22 7.27 7.03 8.70 9.14
investor education and pr... 0.30 0.30 - 0.30 0.30
kotak emerging equity sch... 3.64 3.71 3.70 4.96 5.13
kotak funds - india midca... 1.29 1.29 1.36 1.36 1.36
llp 0.04 0.07 0.04 0.03 0.04
nippon life india trustee... 1.47 1.62 1.70 1.89 1.91
parag parikh flexi cap fu... 1.46 1.46 1.46 1.46 1.46
sbi life insurance co. lt... 1.67 1.73 1.83 2.01 2.20
abu dhabi investment auth... - 1.03 1.12 1.00 -
icici prudential balanced... - - - 1.52 -
icici prudential multi-as... 3.14 2.74 2.40 - -
investor education and pr... - - 0.30 - -
uti flexi cap fund 1.08 1.13 1.04 - -
mirae asset emerging blue... 1.86 - - - -

Ratings & Research Reports

Company Presentations

Company News

Ipca Laboratories secures approval for voluntary closure of Mexico-based subsidiary 5 Dec, 12:21 PM Ipca Laboratories informs about newspaper publication 15 Nov, 5:14 PM Ipca Laboratories - Quaterly Results 14 Nov, 1:19 PM Ipca Laboratories - Quaterly Results 14 Nov, 1:19 PM Ipca Laboratories - Quaterly Results 14 Nov, 1:19 PM Ipca Laboratories informs about loss of share certificate 4 Oct, 12:41 PM Ipca Laboratories informs about notice of board meeting and trading window closure 23 Sep, 12:42 PM Ipca Laboratories informs about disclosure 20 Sep, 11:09 AM IPCA Laboratories informs about analyst meet outcome 19 Aug, 1:04 PM Ipca Laboratories launches Diulcus 17 Aug, 11:57 AM Ipca Laboratories - Quaterly Results 13 Aug, 1:13 PM Ipca Laboratories - Quaterly Results 13 Aug, 1:13 PM Ipca Laboratories - Quaterly Results 13 Aug, 1:13 PM IPCA Laboratories informs about disclosure 7 Aug, 12:12 PM Ipca Laboratories informs about media release 6 Aug, 3:08 PM IPCA Laboratories informs about details of loss of certificate 26 Jul, 4:24 PM Ipca Laboratories informs about board meeting 24 Jul, 2:12 PM Ipca Laboratories informs about loss of share certificate 18 Jul, 5:20 PM Ipca Laboratories informs about book closure 18 Jul, 11:53 AM IPCA Laboratories informs about business responsibility and sustainability report 17 Jul, 12:29 PM Ipca Laboratories informs about annual report 17 Jul, 10:15 AM Ipca Laboratories informs about trading window closure 21 Jun, 12:39 PM Ipca Laboratories informs about issuance of duplicate share certificate 14 Jun, 11:06 AM Ipca Laboratories informs about audio link of conference call 31 May, 1:01 PM Ipca Laboratories - Quaterly Results 29 May, 1:40 PM Ipca Laboratories - Quaterly Results 29 May, 1:40 PM Ipca Laboratories - Quaterly Results 29 May, 1:40 PM Ipca Laboratories informs about loss of share certificates 24 May, 12:19 PM Ipca Laboratories informs about loss of share certificates 6 May, 2:58 PM Ipca Laboratories informs about compliance certificate 22 Apr, 12:32 PM Ipca Laboratories enters into Technology Transfer Agreement with Omexa Formulary 27 Mar, 3:14 PM Ipca Laboratories informs about trading window closure 21 Mar, 3:17 PM Ipca Laboratories informs about press release 27 Feb, 4:34 PM IPCA Laboratories informs about postal ballot notice 27 Feb, 1:03 PM Ipca Laboratories informs about notice of postal ballot 23 Feb, 2:50 PM Ipca Laboratories informs about audio recording of conference call 16 Feb, 10:42 AM Ipca Laboratories - Quaterly Results 14 Feb, 1:42 PM Ipca Laboratories - Quaterly Results 14 Feb, 1:42 PM Ipca Laboratories - Quaterly Results 14 Feb, 1:42 PM lpca Laboratories informs about loss of share certificate 25 Jan, 2:20 PM IPCA Laboratories submits board meeting intimation 22 Jan, 2:52 PM Ipca Laboratories informs about compliance certificate 10 Jan, 2:33 PM Ipca Laboratories informs about loss of share certificate 22 Nov, 3:23 PM Ipca Laboratories informs about press release 13 Nov, 5:01 PM Ipca Laboratories reports 6% fall in Q2 consolidated net profit 13 Nov, 3:12 PM Ipca Laboratories informs about loss of share certificate 13 Nov, 2:51 PM Ipca Laboratories - Quaterly Results 10 Nov, 1:39 PM Ipca Laboratories - Quaterly Results 10 Nov, 1:39 PM Ipca Laboratories - Quaterly Results 10 Nov, 1:39 PM Ipca Laboratories gets VAI classification for Indore facility 31 Oct, 11:52 AM

Ipca Laboratories Stock Price Analysis and Quick Research Report. Is Ipca Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ipca Laboratories and its performance over the period of time. Ipca Laboratories stock price today is Rs 1538.2.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ipca Laboratories cash from the operating activity was Rs 830.51 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ipca Laboratories has a Debt to Equity ratio of 0.1784 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ipca Laboratories , the EPS growth was 4.8864 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ipca Laboratories has OPM of 19.0202251447569 % which is a good sign for profitability.
     
  • ROE: Ipca Laboratories have a poor ROE of 8.6767 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ipca Laboratories is Rs 1538.2. One can use valuation calculators of ticker to know if Ipca Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Ipca Laboratories

Ipca Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Ipca Laboratories Ltd. is a leading pharmaceutical company in India that specializes in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs).  We will take a closer look at Ipca Laboratories Ltd. stock analysis page and explore various aspects of the company that can help long-term investors make informed investment decisions.

Ipca Laboratories Ltd Share Price

Ipca Laboratories Ltd.'s share price has been on a steady upward trend in recent years. The company's strong financial performance and growth prospects have attracted a lot of investor interest, leading to an increase in demand for its shares. Investors can track the company's share price on Ticker's stock analysis page, which provides real-time updates on the stock's performance.

Ipca Laboratories Ltd Balance Sheet

Ipca Laboratories Ltd.'s balance sheet is a reflection of its financial health and stability. The company has a strong balance sheet, with a healthy mix of debt and equity. Ticker pre-built screening tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis can help investors evaluate the company's financial performance and calculate its fair value. Investors can access the company's balance sheet on Ticker's stock analysis page, along with other financial data such as quarterly results and profit and loss statements.

Ipca Laboratories Ltd Annual Report

Ipca Laboratories Ltd.'s annual report provides a comprehensive overview of the company's performance over the past year. The report includes detailed information on the company's financials, operations, and growth prospects. Investors can download the company's annual report from Ticker's stock analysis page. The report can help investors gain a better understanding of the company's business model, competitive landscape, and growth potential.

Ipca Laboratories Ltd Dividend

Ipca Laboratories Ltd. has a track record of paying dividends to its shareholders. The company's dividend policy is based on its financial performance and growth prospects. Investors can access the company's dividend history on Ticker's stock analysis page. 

Ipca Laboratories Ltd Quarterly Result

Ipca Laboratories Ltd.'s quarterly results provide a snapshot of the company's financial performance over the past quarter. The results include information on the company's revenue, profits, and margins. Investors can download the company's quarterly results from Ticker's stock analysis page. Ticker pre-built screening tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis can help investors evaluate the company's financial performance and calculate its fair value.

Ipca Laboratories Ltd Stock Price

Ipca Laboratories Ltd.'s stock price is a reflection of its financial performance and growth prospects. The company's stock price is influenced by various factors such as market trends, investor sentiment, and the company's financials. Investors can track the company's stock price on Ticker's stock analysis page, which provides real-time updates on the stock's performance.

Ipca Laboratories Ltd Price Chart

Ipca Laboratories Ltd.'s price chart provides a visual representation of the company's stock price movement over a period. The chart includes information on the company's stock price, volume, and trends. Investors can access the company's price chart on Ticker's stock analysis page. The chart can help investors gain insights into the company's stock price movement and identify trends.

Ipca Laboratories Ltd News

Ipca Laboratories Ltd.'s news section provides updates on the company's latest developments and announcements. The section includes information on the company's product launches, partnerships, and collaborations. Investors can access the company's news section on Ticker's stock analysis page. The news section can help investors stay updated on the company's latest developments and make informed investment decisions.

Ipca Laboratories Ltd Concall Transcripts

Ipca Laboratories Ltd.'s concall transcripts provide a detailed account of the company's earnings conference call. The transcripts include information on the company's financial performance, growth prospects, and future plans. Investors can download the company's concall transcripts from Ticker's stock analysis page. The transcripts can help investors gain insights into the company's performance and future prospects.

Ipca Laboratories Ltd Investor Presentations

Ipca Laboratories Ltd.'s investor presentations provide a detailed overview of the company's business model, operations, and growth prospects. The presentations include information on the company's financials, product portfolio, and competitive landscape. Investors can download the company's investor presentations from Ticker's stock analysis page. The presentations can help investors gain a better understanding of the company's business model and growth potential.

Ipca Laboratories Ltd Promoters

Ipca Laboratories Ltd.'s promoters are the key drivers of the company's growth and success. The promoters have a significant stake in the company and are actively involved in its operations and decision-making. Investors can access information on the company's promoters on Ticker's stock analysis page. The information can help investors evaluate the promoters' track record and their contribution to the company's growth.

Ipca Laboratories Ltd Shareholders

Ipca Laboratories Ltd.'s shareholders are the owners of the company and have a stake in its financial performance and growth prospects. The company has a diverse shareholder base, including institutional investors and retail investors. Investors can access information on the company's shareholders on Ticker's stock analysis page. The information can help investors evaluate the company's shareholder base and their contribution to the company's growth.

Ipca Laboratories Ltd ROCE

Ipca Laboratories Ltd ROCE (Return on Capital Employed) measures the profitability and efficiency of the company's capital investments. It indicates how well the company generates returns from its capital employed. The ROCE can be obtained from the financials table or ratio section provided on this page.

Ipca Laboratories Ltd EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Ipca Laboratories Ltd provides insights into the company's operational profitability. This metric reflects the company's ability to generate earnings from its core business operations, excluding non-operating factors. For detailed EBITDA data, refer to the above financials table or ratio section.

Ipca Laboratories Ltd DPS

Ipca Laboratories Ltd DPS (Dividends Per Share) represents the amount of cash distributed to shareholders for each share held. It allows investors to assess the company's dividend policy and potential returns. The DPS information for Ipca Laboratories Ltd can be found in the above financials table or ratio section.

Ipca Laboratories Ltd EPS

The EPS (Earnings Per Share) of Ipca Laboratories Ltd is a crucial metric that shows the company's profitability on a per-share basis. It is obtained by dividing the company's earnings by the total outstanding shares. Investors can find the EPS data for Ipca Laboratories Ltd in the above financials table or ratio section on this page.

Read More
X